1. Home
  2. EH vs RIGL Comparison

EH vs RIGL Comparison

Compare EH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

HOLD

Current Price

$9.37

Market Cap

679.5M

Sector

Industrials

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$28.44

Market Cap

564.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EH
RIGL
Founded
2014
1996
Country
China
United States
Employees
483
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
679.5M
564.7M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
EH
RIGL
Price
$9.37
$28.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$22.47
$45.67
AVG Volume (30 Days)
522.9K
397.1K
Earning Date
05-26-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1867.68
EPS
N/A
0.44
Revenue
N/A
$294,282,000.00
Revenue This Year
$33.23
N/A
Revenue Next Year
$73.83
$12.75
P/E Ratio
N/A
$64.55
Revenue Growth
N/A
64.15
52 Week Low
$9.04
$18.14
52 Week High
$20.44
$52.24

Technical Indicators

Market Signals
Indicator
EH
RIGL
Relative Strength Index (RSI) 38.72 46.60
Support Level $9.15 $28.08
Resistance Level $10.68 $31.89
Average True Range (ATR) 0.42 1.96
MACD -0.06 0.05
Stochastic Oscillator 23.17 39.02

Price Performance

Historical Comparison
EH
RIGL

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Share on Social Networks: